Eli Lilly to buy diabetes cell therapy partner Sigilon, expanding bet on preclinical program

Kyle LaHucik

Senior Reporter

Eli Lilly will buy its diabetes cell therapy partner Sigilon Therapeutics, which came out of Flagship Pioneering, about five years after the two companies first …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eli Lilly to buy diabetes cell therapy partner Sigilon, expanding bet on preclinical program

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Are programs with compounded GLP-1s safe for your population?

Eli Lil­ly to buy di­a­betes cell ther­a­py part­ner Sig­ilon, ex­pand­ing bet on pre­clin­i­cal pro­gram

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Eli Lilly to buy diabetes cell therapy partner Sigilon, expanding bet on preclinical program

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Are programs with compounded GLP-1s safe for your population?